



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,715	05/14/2007	Sergey I. Chernysh	SPSUP0100WOUS	4071
23908 7590 03/10/2010 RENNER OTTO BOISSELLE & SKLAR, LLP 1621 EUCLID AVENUE NINETEENTH FLOOR CLEVELAND, OH 44115			EXAMINER GUSSOW, ANNE	
			ART UNIT 1643	PAPER NUMBER
			MAIL DATE 03/10/2010	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/585,715	Applicant(s) CHERNYSH ET AL.	
	Examiner Anne M. Gussow	Art Unit 1643	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 January 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,5,7-10,14,15 and 17-20 is/are pending in the application.
- 4a) Of the above claim(s) 18-20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,5 and 7-10 is/are rejected.
- 7) ☒ Claim(s) 14,15 and 17 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 1 and 10 have been amended.

Claims 2-4, 6, 11-13, 16, and 21-26 have been cancelled.

Claims 18-20 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on December 17, 2008.

2. Claims 1, 5, 7-10, 14, 15, and 17 are under examination.

3. The following office action contains NEW GROUNDS of Rejection.

Objections Withdrawn

4. The objection to the specification is withdrawn in view of applicant's amendment to the specification.

Rejections Withdrawn

5. The rejection of claims 1, 2, 6-17, and 22-26 under 35 U.S.C. 102(b) as being anticipated by Fishleigh, et al. is withdrawn in view of applicant's amendment to the claims.

Rejections Maintained/ NEW GROUNDS of Rejection

Claim Objections

6. Claim 2 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Claim 2 is drawn to a broader group of peptides than the peptide in claim 1.

7. Claim 1 is objected to because of the following informalities: the claim contains a peptide sequence which is not identified by SEQ ID No. The sequence appears to be SEQ ID No. 1. Appropriate correction is required.

Claim Rejections - 35 USC § 101

8. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

9. The rejection of claims 1, 5, and 7-10 under 35 U.S.C. 101 as being directed to non-statutory subject matter is maintained.

Applicant's arguments filed January 7, 2010 have been carefully considered by the examiner but they are deemed not to be persuasive. The response states that claim 1 has been amended to recite a peptide having the general structural formula: His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly. The peptide of SEQ ID No. 1 (allostatin-1) of the claimed invention is an artificial sequence, as it is mentioned in the List of

Art Unit: 1643

Sequences, and is significantly different from the structure of any known natural or synthetic peptides represented in Swissprot or other available protein and peptide data bases. It was obtained by the chemical synthesis process described on pages 3 and 6 of the specification. Furthermore, the biological activity of the peptide SEQ ID NO. 1 (allostatin-1) differs from the activity of structurally similar naturally occurring peptide alloferon 1 (SEQ ID No. 12) in the way that makes allostatin-1 more prospective for clinical as is demonstrated in the Example 2 of the specification (see response pages 5-6).

In response to this argument, the peptide sequence of SEQ ID No. 1 does not contain any non-naturally occurring amino acids. The identity of the peptide as an artificial sequence in the sequence listing does not prevent the sequence from being naturally expressed by a cell of as yet unknown identity. Further, applicant's argument that the peptide of SEQ ID No. 2 is naturally occurring and structurally similar supports the possibility of the peptide of SEQ ID No. 1 being naturally expressed but not as yet identified. The claims as written do not distinguish from naturally occurring peptides and are thus drawn to non-statutory subject matter. Amendment of the claims to recite an isolated peptide would obviate this rejection.

Therefore after a fresh consideration of the claims and the evidence provided the rejection is maintained.

Conclusion

10. Claims 1, 5, and 7-10 are rejected.

Claims 14, 15, and 17 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne M. Gussow whose telephone number is (571)272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

Art Unit: 1643

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anne M. Gussow
March 8, 2010

/Anne M. Gussow/
Examiner, Art Unit 1643

/Larry R. Helms/
Supervisory Patent Examiner, Art Unit 1643